Catalyst
Slingshot members are tracking this event:
FDA Concludes that Johnson & Johnson's (JNJ) Blood Thinner XARELTO is Safer Than Bristol-Myers Squibb's (BMY) Warfarin in Patients with Atrial Fibrillation
- Source Link:
- http://www.fda.gov/Drugs/DrugSafety/ucm524678.htm
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 11, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Blood Thinner, Xarelto, Warfarin, Atrial Fibrillation, Fda, Phase 3, Rocket-af, Inratio Device
